anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a pharmaceutical formulation that is stabilized against deamidation and aggregation.  <P>SOLUTION: The invention relates to a pharmaceutical formulation including growth hormone, an amino acid selected from the group of Asp, Ile, Val and Leu, or a derivative of histidine, or a peptide including at least one basic amino acid residue and at least one acidic amino acid residue, and a nonionic detergent, e.g. polysorbate or poloxamer. The pharmaceutical formulation may be an aqueous composition. The growth hormone may be human growth hormone.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Preclinical: Studies in laboratory animals (minipigs, rodents, and dogs) have demonstrated the occurrence of cardiac arrhythmias and sudden death (with histologic evidence of myocardial necrosis) when beta-agonists and methylxanthines are administered concurrently. The clinical relevance of these findings is unknown.

Reproductive Toxicology Studies: No teratogenic effects occurred in rats at oral doses up to 2 mg/kg (approximately 160 times the MRHD on an mg/m2 basis).

In Dutch rabbits administered oral doses of 1 mg/kg and above (approximately 50 times and above the MRHD based on comparison of the AUCs), salmeterol exhibited fetal toxic effects characteristically resulting from beta-adrenoceptor stimulation. These included precocious eyelid openings, cleft palate, sternebral fusion, limb and paw flexures, and delayed ossification of the frontal cranial bones. No such effects occurred at an oral dose of 0.6 mg/kg (approximately 20 times the MRHD based on comparison of the AUCs). New Zealand White rabbits were less sensitive since only delayed ossification of the frontal bones was seen at an oral dose of 10 mg/kg (approximately 1,600 times the MRHD on an mg/m2 basis).

Salmeterol crossed the placenta following oral administration to mice and rats.
The invention provides a proteinaceous molecule comprising a lysine and/or arginine residue and/or a functional equivalent thereof, capable of providin g enhanced levels of plasmin in a mammalian through tPA mediated plasminogen activation for use as a pharmaceutical. The invention further provides use o f a proteinaceous molecule according to the invention for the preparation of a  medicament for the treatment of diseases related with angiogenesis and/or inflammatory disorders and/or conformational disorders and/or ageing. Furthermore the invention provides a proteinaceous molecule to suppress tumo r growth, to regress established tumors, to degrade amyloid-.beta. and to inhibit amyloid-.beta. action. Additionally the invention provides a method for the treatment of a disease associated with or dependent on angiogenesis and/or associated with amyloid deposition comprising administering to a patient an effective amount of a proteinaceous molecule comprising a lysine and/or arginine residue and/or a functional equivalent thereof, capable of providing enhanced levels of plasmin in a mammalian through tPA mediated plasminogen activation.
The invention discloses a 2,2-dimethyl benzopyran compound and a preparation method and application thereof, belonging to the technical field of medicines. The structure of the 2,2-dimethyl benzopyran compound is shown in a figure described in the specification. The preparation method of the 2,2-dimethyl benzopyran compound comprises the following steps of: with 2-methyl-butyl-3-alkyne-2 alcohol as a starting raw material, carrying out four-step reactions comprising chlorination, Williamson etherification, cyclization and Aldol condensation to obtain the  2,2-dimethyl benzopyran compound. The preparation method of the 2,2-dimethyl benzopyran compound, disclosed by the invention, has the advantages of simple operation, convenience for post-treatment and higher yield. The 2,2-dimethyl benzopyran compound has an excellent inhibition function on various cancer cells so as to be applied to treatment of tumors. A formula is described in the specification, wherein R' represents H and C1-6 alkyl and R represents substituted or unsubstituted aromatic ring or heteroaromatic ring.
The present disclosure provides pharmaceutical agents, including those of the formula:(I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents are also provided. The compounds may be used for the inhibition or antagonism of integrins a?ß? and/or a5ß?. In some embodiments, the compounds provided herein exhibit reduced inhibitory or antagonistic activity of integrins a?ß3, a?ß5, a?ß6, a?ß8, and/or aIIbß3.
The present invention relates to the composition for the low viscosity mixtures for forming following components：A. at least one diacylglycerol and/or at least one tocopherol；B. at least one phospholipid fraction, it includes having following phosphatide：I. the polar head group more than 50% phosphatidyl-ethanolamine is included; with two acyl chains of ii.; each acyl chain independently has 16 to 20 carbon, and wherein at least one acyl chain has at least one degree of unsaturation in carbochain, and has not more than four degrees of unsaturation in two carbochains；C. at least one bio-compatible, oxygen containing, low viscosity organic solvent；Wherein optionally at least a kind of bioactivator is dissolved or dispersed in the low viscosity mixtures；And wherein described preformulation forms or can formed at least one non-laminar liquid crystalline phase structure when being contacted with aqueous fluid.The invention further relates to the treatment method for including composition as administration, and it is related to pre-filled application device and medicine box comprising preparation.
In the cross-sectional part, the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by traditional sleep monitoring equipment (polysomnography) and millimeter wave radar equipment. In the cohort part, this group of patients will be continuously monitored by millimeter wave radar equipment for vital signs combined with pulse oxygen saturation, end expiratory CO2 and other indicators continuously monitored.
Recent studies have reported the presence of autoantibodies against zinc finger and SCAN domain-containing protein 1 (ZSCAN1) in the sera of patients with rapid-onset obesity with hypoventilation, hypothalamic and autonomic dysregulation (ROHHAD) syndrome associated with neuroendocrine tumors, suggesting immunologic and paraneoplastic processes as the pathologic underpinnings. Moreover, several hypothalamic regions, including the subfornical organ (SFO), were reported to exhibit antibody reactivity in a patient with ROHHAD syndrome not associated with a tumor. Whether ROHHAD syndrome not associated with a tumor is associated with anti-ZSCAN1 autoantibodies remains unclear. We used a comprehensive protein array analysis to identify candidate molecules in the sera of patients with ROHHAD syndrome and identified ZSCAN1 as a target antigen. We also found that ZSCAN1 was co-expressed at the site of antibody reactivity to the IgG in the patient serum observed in mouse SFOs and an enzyme-linked immunosorbent assay showed that >85% of the patients with ROHHAD syndrome were positive for anti-ZSCAN1 autoantibodies. These results suggest anti-ZSCAN1 autoantibodies as a feasible diagnostic marker in ROHHAD syndrome regardless of the presence of a tumor.
1388719 T-globulin and anti-serum therefor HADASSAN MEDICAL RELIEF ASSOCIATION Inc 1 Sept 1972 [2 Sept 1971] 40595/72 Heading A5B [Also in Division G1] The invention comprises pure T-globulin, i.e. a globulin fraction of M.W. 115,000-170,000 detectable in the blood of pregnant women and cancer sufferers, which when precipitated from serum and subjected to electrophoresis as below migrates towards the positive electrode at 5mm/hr. The electrophoresis is carried out in an agar block measuring 75mm (between the electrodes) x 25mm x 4mm, the current is 10mA, the voltage gradient is 4.5 volts/cm and the agar is buffered at pH 8.6. In preparing T-globulin, blood serum from cancer-sufferers and for pregnant women is treated with saturated ammonium sulphate to precipitate the globulin, from which the appropriate molecular weight fraction is collected as follows: (a) The globulin is dissolved in water (b) a precipitate is formed by addition of perchloric acid, (c) the precipitate is washed with neutral saline, (d) the precipitate is extracted with saline at pH 7.8-8.2 to dissolve out the T- globulin. T-globulin anti serum may be prepared by injecting T-globulin and Freund's complete adjuvant into a mammal. The antiserum may be purified by electrophoresis or by precipitation with perchloric acid followed by re-solution at pH 7.8-8.2. It may further be purified by treating it with normal blood serum to precipitate out all the anti-bodies except anti-T-globulin.
A composition comprising a mixture of Allium sativum, Ferula assa-foetida, Curcuma longa, Acacia nilotica, Calligonum comosum, Phoenix dactylifera with sodium chloride is provided. The composition may further comprise honey. The mixture of said composition may be burnt. The composition may be mixed with at least one of water, honey, cream, oil or a gel. A method for the preparation of a composition comprising mixing Allium sativum (garlic), Ferula assa-foetida (Asafoetida, dried latex of Ferula species), Curcuma longa (turmeric), Acacia nilotica (gum Arabic tree), Calligonum comosum, Phoenix dactylifera (dates) with sodium chloride and burning the mixture to produce a powdery composition is provided. The method may further comprise mixing the powdery composition with honey. The method may further comprise mixing the powdery composition in at least one of water, honey, cream, oil or a gel. The use of said composition for the treatment of gangrene, skin ulcers or eczema is provided.
Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
INTRODUCTION: Chronic obstructive pulmonary disease is a systemic disease characterized not only by respiratory symptoms but also by physical deconditioning and muscle weakness. One prominent manifestation of this disease is the decline in respiratory muscle strength. Previous studies have linked the genotypes of insulin-like growth factor 1 and 2 (IGF-1 and IGF-2) to muscle weakness in other populations without this disease. However, there is a notable knowledge gap regarding the biological mechanisms underlying respiratory muscle weakness, particularly the role of IGF-1 and IGF-2 genotypes in this pulmonary disease. Therefore, this study aimed to investigate, for the first time, the association between IGF-1 and IGF-2 genotypes with respiratory muscle strength in individuals with chronic obstructive pulmonary disease. In addition, we analyzed the relationship between oxidative stress, chronic inflammation, and vitamin D with respiratory muscle strength.
METHODS: A cross sectional study with 61 individuals with chronic obstructive pulmonary disease. Polymerase chain reaction of gene polymorphisms IGF-1 (rs35767) and IGF-2 (rs3213221) was analyzed. Other variables, related to oxidative stress, inflammation and Vitamin D were dosed from peripheral blood. Maximal inspiratory and expiratory pressure were measured.
RESULTS: The genetic polymorphisms were associated with respiratory muscle strength ( 3.0 and 3.5; = 0.57). Specific genotypes of IGF-1 and IGF-2 presented lower maximal inspiratory and expiratory pressure (<0.05 for all). Oxidative stress, inflammatory biomarkers, and vitamin D were not associated with respiratory muscle strength.
CONCLUSION: The polymorphisms of IGF-1 and IGF-2 displayed stronger correlations with respiratory muscle strength compared to blood biomarkers in patients with chronic obstructive pulmonary disease. Specific genotypes of IGF-1 and IGF-2 were associated with reduced respiratory muscle strength in this population.
This is an observational, cross-sectional study. For the purposes of the study a sample group was selected from a clinic specialised in ACL reconstruction and rehabilitation based in Athens, Greece. Patients of the specific clinic had received the same surgical technique and rehabilitation protocol. Ability to return to sport was examined 9 months after surgery and approval was given according to the rehabilitation progress. A list of eligible study subjects was formed and, after inclusion and exclusion criteria were screened for, they were invited to participate in the study. Study participants, after having declared consent and passed the criteria were asked to answer the study questionnaires. Communication with participants was done through telephone and email, and all questionnaires were completed online.
Cardiac arrhythmias are the leading cause of death and pose a huge health and economic burden globally. Electrocardiography (ECG) is an effective technique for the diagnosis of cardiovascular diseases because of its noninvasive and cost-effective advantages. However, traditional ECG analysis relies heavily on the clinical experience of physicians, which can be challenging and time-consuming to produce valid diagnostic results. This work proposes a new hybrid deep learning model that combines convolutional neural network (CNN) and bidirectional gated recurrent unit (BiGRU) with multi-head attention (CBGM model). Specifically, the model consists of seven convolutional layers with varying filter sizes (4, 16, 32, and 64) and three pooling layers, respectively, while the BiGRU module includes two layers with 64 units each followed by multi-head attention (8-heads). The combination of CNN and BiGRU effectively captures spatio-temporal features of ECG signals, with multi-head attention comprehensively extracted global correlations among multiple segments of ECG signals. The validation in the MIT-BIH arrhythmia database achieved an accuracy of 99.41%, a precision of 99.15%, a specificity of 99.68%, and an F1-Score of 99.21%, indicating its robust performance across different evaluation metrics. Additionally, the model's performance was evaluated on the PTB Diagnostic ECG Database, where it achieved an accuracy of 98.82%, demonstrating its generalization capability. Comparative analysis against previous methods revealed that our proposed CBGM model exhibits more higher performance in automatic classification of arrhythmia and can be helpful for assisting clinicians by enabling real-time detection of cardiac arrhythmias during routine ECG screenings.
Drugs: Nab-paclitaxel. Gemcitabine - 28 day cycle. 9-ING-41.
Patients receive autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV between 24-96 hours after the last dose of chemotherapy and receive aldesleukin SC BID for 14 days. Patients then undergo surgery within 3-4 weeks after the T-cell infusion.
Radiofrequency Ablation is carried out under intravenous anesthesia/epidural anesthesia/general anesthesia, with CT or B-ultrasound guidance, through percutaneous or laparoscopic means as far as possible. The ablation range requires complete coverage of the tumor, and has a certain "safe margin". CT/MRI/sonography will be performed 1 month after RFA. If residual tumor was found after treatment, RFA will be carried out again. If there are still residual tumor after two or more RFA treatments, the RFA treatment will be stopped. After the local progression of the tumor, surgical treatment or other treatment methods are considered according to the specific condition.
There exists no cure for acute, recurrent acute or chronic pancreatitis and treatments to date have been focused on managing symptoms. A recent workshop held by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) focused on interventions that might disrupt or perhaps even reverse the natural course of this heterogenous disease, aiming to identify knowledge gaps and research opportunities that might inform future funding initiatives for NIDDK. The breadth and variety of identified active or planned clinical trials traverses the spectrum of the disease and was conceptually grouped for the workshop into behavioral, nutritional, pharmacologic and biologic, and mechanical interventions. Cognitive and other behavioral therapies are proven interventions for pain and addiction, but barriers exist to their use. Whilst a disease specific instrument quantifying pain is now validated, an equivalent is lacking for nutrition - and both face challenges in ease and frequency of administration. Multiple pharmacologic agents hold promise. Ongoing development of Patient Reported Outcome (PRO) measurements can satisfy Investigative New Drug (IND) regulatory assessments. Despite multiple randomized clinical trials demonstrating benefit, great uncertainty remains regarding patient selection, timing of intervention, and type of mechanical intervention (endoscopic versus surgery). Challenges and opportunities to establish beneficial interventions for patients were identified.
Use of MPA Injectable Suspension, USP reduces serum estrogen levels and is associated with significant loss of bone mineral density (BMD). This loss of BMD is of particular concern during adolescence and early adulthood, a critical period of bone accretion. It is unknown if use of MPA Injectable Suspension, USP by younger women will reduce peak bone mass and increase the risk for osteoporotic fracture in later life.

A study to assess the reversibility of loss of BMD in adolescents was conducted with MPA Injectable Suspension, USP. After discontinuing MPA Injectable Suspension, USP in these adolescents, mean BMD loss at the total hip and femoral neck did not fully recover by 5 years (60 months) post-treatment in the sub-group of adolescents who were treated for more than 2 years [see Clinical Studies (14.3)]. Similarly, in adults, there was only partial recovery of mean BMD at the total hip, femoral neck and lumbar spine towards baseline by 2 years post-treatment. [see Clinical Studies (14.2)].

The use of MPA Injectable Suspension, USP is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate. BMD should be evaluated when a woman needs to continue to use MPA Injectable Suspension, USP long-term. In adolescents, interpretation of BMD results should take into account patient age and skeletal maturity.

Other birth control methods should be considered in the risk/benefit analysis for the use of MPA Injectable Suspension, USP in women with osteoporosis risk factors. MPA Injectable Suspension, USP can pose an additional risk in patients with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids).
Following a single dose of Minocin 200 mg administered intravenously to 10 healthy male subjects, serum concentrations of minocycline ranged from 2.52 to 6.63 mcg/mL (average 4.18 mcg/mL) at the end of infusion and 0.82 to 2.64 mcg/mL (average 1.38 mcg/mL) after 12 hours. In a group of 5 healthy male subjects, serum concentrations of minocycline ranged from 1.4 to1.8 mcg/mL at the end of the dosing interval following administration of Minocin 100 mg every 12 hours for three days. When Minocin 200 mg once daily was administered for three days, serum concentrations of minocycline were approximately 1 mcg/mL at 24 hours. The serum elimination half-life of minocycline following administration of either Minocin 100 mg every 12 hours or 200 mg once daily was not significantly different and ranged from 15 to 23 hours. The serum elimination half-life of minocycline ranged from 11 to 16 hours in subjects with hepatic impairment (n=7) and 18 to 69 hours in subjects with renal impairment (n=5). In comparison, the serum elimination half-life of minocycline ranged from 11 to 17 hours following a single dose of oral minocycline 200 mg in healthy subjects (n=12).
A sutured mucopexy is an operation performed under general anaesthesia. At 4 cm proximal of the dentate line, a Z- shaped stitch through the rectal wall is placed and then at the upper level of the haemorrhoidal tissue, pulling up the prolapsing haemorrhoid high into the anal canal.
Hyperbaric oxygen therapy allows the patient to breathe 100% oxygen through an O2 Fresh M50 (HBOT Medical, Wonju, South Korea) chamber. Upon entering the chamber, oxygen is supplied while gradually increasing the atmospheric pressure from normal atmospheric pressure to 1.5 atmospheres absolute (ATA). If the intensity acceptable to the clinical research subject is lower than 1.5 ATA, maintain it at the point acceptable to the research subject and record that value.
An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.
The invention belongs to the technical field of traditional Chinese medicines (TCMs) and provides a medicine used for treating eczema, aiming to solve the problem of treating eczema. The medicine is prepared from radix rehmanniae, Sichuan lovage rhizome, Chinese angelica, radix paeoniae alba, stiff silkworm, divaricate saposhnikovia root, cortex dictamni, cicada slough, amur corktree bark, oriental waterplantain rhizome, plantain seed, raw seeds of Job's tears, poria cocos, talc, tetrapanax papyriferus and atractylodes macrocephala according to a certain proportion. A preparation method of the medicine is characterized by comprising the following steps: after mixing the medicines, adding 600ml of water to a first dose to decoct the first dose until 200ml and adding 500ml of water to a second dose to decoct the second dose until 200ml. The medicine is taken on an empty stomach respectively in the morning and in the evening each day. In the TCM preparation, radix rehmanniae, Sichuan lovage rhizome, Chinese angelica, radix paeoniae alba, stiff silkworm and divaricate saposhnikovia root have the function of nourishing the blood to expel wind; cortex dictamni, cicada slough and amur corktree bark have the function of eliminating dampness to relieve itching; oriental waterplantain rhizome, plantain seed, raw seeds of Job's tears, poria cocos, talc, tetrapanax papyriferus and atractylodes macrocephala have the function of excreting dampness to transform turbidity. Through compatibility and synergy of the medicines, the medicine has good curative effects on eczema.